Sartorius Stedim Biotech reported preliminary fiscal 2024 net profit of 175.1 million euros, down 43.6% from last year. Earnings per share was 1.81 euros compared to 3.37 euros. Underlying EBITDA was down 0.8% to 779 million euros. Underlying earnings per share were 3.49 euros compared to 4.19 euros.
In 2024, sales revenue was 2.78 billion euros, up 0.2% reported, up 0.6% in constant currencies, and a decline of 0.7% in constant currencies on an organic basis. Order intake increased by a double-digit 12.9% in constant currencies or up 12.3% reported.
Fourth quarter sales revenue was 751 million euros, up 6.1% in constant currencies, or up 6.3% as reported. Order intake rose significantly by 23.8% in constant currencies.
For 2025, management expects profitable, moderate growth above market level. The company intends to grow profitably above market level, and to achieve a moderate increase in sales revenue. The company forecasts that underlying EBITDA should increase over-proportionately compared with sales revenue.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.